De Novo device
Control-IQ Technology
Tandem Diabetes Care, Inc. · Interoperable Automated Glycemic Controller (QJI, Class II) · First FDA decision Dec 13, 2019, newest Nov 3, 2023Diabetes
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
De Novo pathway
Device trials
46
Naming "Control-IQ Technology"
MAUDE reports
740,761
Brand "Control-IQ Technology", since 2015
PubMed studies
59
Mentioning "Control-IQ Technology"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Control-IQ Technology
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- Control-IQ Technology510(k)
K232382 · Decided Nov 3, 2023 · 87 days after receipt
Device type: Interoperable Automated Glycemic Controller (QJI) · Laboratory Medicine & Pathology
- Control-IQ Technology510(k)
K200467 · Decided Jun 16, 2020 · 111 days after receipt
Device type: Interoperable Automated Glycemic Controller (QJI) · Laboratory Medicine & Pathology
- Control-IQ TechnologyNew device typeDe Novo
DEN190034 · Decided Dec 13, 2019 · 151 days after receipt
Device type: Interoperable Automated Glycemic Controller (QJI) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Control-IQ Technology", any status and sponsor, newest update first.
- The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in FranceRecruiting
Tandem Diabetes Care, Inc.Public (TNDM)
NCT07211126 · 350 participants (planned) · Start Mar 3, 2026 · Primary completion Dec 2027
Device: t:slim X2 insulin pump with Control-IQ technology (Control-IQ System) · For: Diabetes Mellitus, Type 1
Sites: Agen, France; Angers, France; Bron, France · 25 sites in all
McGill UniversityAcademic, hospital or other
NCT07348432 · 106 participants (planned) · Start Jul 29, 2024 · Primary completion Oct 31, 2026
Device: Automated Insulin Delivery (AID) Systems · For: Insulin Dependent Diabetes Mellitus; Feeding and Eating Disorders; Eating Behavior and 3 more
Sites: Montreal, Canada
Mark D. DeBoer, MD, MSc., MCRAcademic, hospital or other
NCT06948760 · 11 participants · Start Jul 23, 2025 · Primary completion Feb 27, 2026
Device: Control-IQ insulin pump with Lyumjev insulin; Control-IQ insulin pump with Humalog or Novolog · For: Type 1 Diabetes
Sites: Charlottesville, Virginia
43 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Control-IQ Technology", and for the whole product code for context.
This brand
740,761 reports: 664,073 malfunction, 76,573 injury, 115 death
Whole product code QJI
5,524 reports: 3,680 malfunction, 1,836 injury, 4 death
Newest reports for this brand
3013756811-2026-197917 · Received Oct 30, 2026 · Event dated Oct 9, 2026
Device type: Alternate Controller Enabled Insulin Infusion Pump (QFG)
Device problem as coded: Obstruction of Flow
Patient problem as coded: Hyperglycemia; Elevated Ketones/ Diabetic Ketoacidosis
3013756811-2026-197914 · Received Oct 30, 2026 · Event dated Oct 10, 2026
Device type: Alternate Controller Enabled Insulin Infusion Pump (QFG)
Device problem as coded: Obstruction of Flow
Patient problem as coded: Hyperglycemia
3013756811-2026-197913 · Received Oct 30, 2026 · Event dated Jul 18, 2026
Device type: Alternate Controller Enabled Insulin Infusion Pump (QFG)
Device problem as coded: Obstruction of Flow
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1636-2026 · Started Jan 30, 2026 · Posted by FDA Mar 25, 2026
Reason given: The Czech language user guide contained multiple translation errors. The most significant error was that it incorrectly instructs users to verify that the infusion set is connected to the body, when it should instead direct users to confirm that the infusion set is not connected to the body. Following this instruction...
Cause as FDA categorized it: Process change control · Device type: Alternate Controller Enabled Insulin Infusion Pump (QFG)
Published research
The most relevant PubMed records for "Control-IQ Technology"[tiab]. The summary above synthesizes these.
- Rethinking control-IQ+ technology: Simple strategies for easy optimization.
Shah VN, Choudhary P, Halperin I, et al. · Diabetes Obes Metab · 2026Review
- Control-IQ Technology Use in Individuals With High Insulin Requirements: Results From the Multicenter Higher-IQ Trial.
Carlson AL, Graham TE, Akturk HK, et al. · J Diabetes Sci Technol · 2024Multicenter Study, Clinical Trial
- HEDIS glycemic goal achieved using control-IQ Technology.
Patel BV, Wang SM, Messer LH, et al. · Am J Manag Care · 2025
- Control-IQ technology enhanced by educative path in diabetes children.
Scaramuzza A, Cavalli C, Rabbone I · Diabetes Res Clin Pract · 2020Letter, Comment
- Efficacy of Control-IQ Technology in a General Endocrine Clinic.
Usoh CO, Price C, Johnson CP, et al. · Endocr Pract · 2023
- Control-IQ Technology Provides Similar Glycemic Outcomes Across Two Different Continuous Glucose Monitoring Sensors.
Akturk HK, Johnson AK, Welsh JB, et al. · J Diabetes Sci Technol · 2026Comparative Study
- Real-world use of Control-IQࡊ technology automated insulin delivery in pregnancy: A case series with qualitative interviews.
Wang XS, Dunlop AD, McKeen JA, et al. · Diabet Med · 2023Research Support, Non-U.S. Gov't
- Control-IQ Technology Positively Impacts Patient Reported Outcome Measures and Glycemic Control in Youth with Type 1 Diabetes in a Real-World Setting.
Zuijdwijk C, Courtney J, Mitsakakis N, et al. · Pediatr Diabetes · 2023Observational Study, Research Support, Non-U.S. Gov't
- Implementing Control-IQ technology after a virtual educational camp in children and adolescents with type 1 diabetes: Does time in range plateau over 1 year?
Scaramuzza AE, Marigliano M, Bonfanti R, et al. · Diabetes Obes Metab · 2024Letter
- The Effect of Control IQ Hybrid Closed Loop Technology on Glycemic Control in Adolescents and Adults with Cystic Fibrosis-Related Diabetes.
Scully KJ, Palani G, Zheng H, et al. · Diabetes Technol Ther · 2022Multicenter Study, Research Support, N.I.H., Extramural
- First Use of Control-IQ+ Technology in Newly Indicated Populations.
Assadi KZ, D'Souza EW, Pinsker JE, et al. · Diabetes Technol Ther · 2026
- The Hybrid Closed-Loop System Tandem t:slim X2ࡊ with Control-IQ Technology: Expert Recommendations for Better Management and Optimization.
Chico A, Moreno-Fernández J, Fernández-García D, et al. · Diabetes Ther · 2024
Other devices of this type
Also filed under product code QJI.
- SmartGuard TechnologyMedtronic MiniMed · 510(k) 2026
- SmartAdjust TechnologyInsulet Corporation · 510(k) 2024
- iLet Dosing Decision SoftwareBeta Bionics, Inc. · 510(k) 2026
- Control-IQ+ technologyTandem Diabetes Care, Inc. · 510(k) 2026
- twiist Loop AlgorithmDeka Research and Development Corp. · 510(k) 2026
- iOS CamAPS FXCamDiab · 510(k) 2026
- Omnipod 6 algorithmInsulet Corporation · 510(k) 2026
- DBLG2Diabeloop · 510(k) 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.